Tag: Featured Story

Expanding your cannabis operation is an exciting milestone, but it’s also the exact moment your bank starts paying closer attention. Every new license, state, or investor changes your company's risk profile in the eyes of financial institutions. If left unmanaged, this newfound complexity can unexpectedly put your banking relationships in jeopardy. Two bankers reveal the hidden risks of rapid expansion, why your bank suddenly has so many questions, and how to successfully scale your business without losing access to crucial financial services.

The “wild west” era of craft-scale cannabis edibles is hitting a multi-billion-dollar wall. As global edibles sales head toward a projected $55 billion over the next decade, market survival relies on operational discipline over flashy packaging. Gummy manufacturing remains incredibly volatile, where slight deviations in climate or timing ruin entire batches. To safely scale, the industry must shift from an artisanal test-kitchen mindset to engineered, standardized foundational formulations.

The historic federal shift reclassifying medical marijuana to Schedule III brings undeniable progress, offering long-awaited tax relief from Section 280E. Yet, despite the initial market excitement, rescheduling is not a cure-all for the industry’s deep-rooted liquidity crisis. Cash buyers remain scarce, transactions rely heavily on seller financing, and regulatory fragmentation persists. True competitive advantage in a mature market won’t come from waiting on Washington. It will come from corporate architecture. Here’s why some cannabis operators are looking past policy hype and leveraging independent buyouts to achieve the ultimate business goal: a tax-free exit.

The same United States House of Representatives that voted to let Veterans Administration doctors help vets access medical cannabis also voted, nearly simultaneously, to block the federal rescheduling process that would make such access legally coherent. That is not mixed signals; it is a fractured federal posture. For the roughly 9 million veterans enrolled in VA healthcare, it lands with consequences that are anything but abstract.

Federal efforts to reschedule cannabis typically are framed as a matter of drug policy, centering on taxation, criminal enforcement, and the plant’s classification under the Controlled Substances Act. Yet, this traditional framing increasingly obscures a deeper regulatory transformation. As a partial shift to Schedule III lowers long-standing barriers to genetic research, cannabis is rapidly entering the agricultural biotechnology era. This scientific leap is setting up an unprecedented collision with an unsettled federal oversight landscape. Regulators must now confront whether advanced cannabis innovations will be governed solely as controlled substances or treated as genetically modified crops subject to complex agricultural pest risk oversight.

In a move that signals massive consolidation in the B2B events space, Apollo Global Management has agreed to acquire Emerald Holding Inc. — parent company of MJBizCon — in a $1.5-billion all-cash deal. The transaction will take the publicly traded Emerald private, merging its portfolio with Questex LLC to create a unified experiential media platform. While the deal reflects Apollo’s broader interest in specialized markets rather than a specific cannabis play, the shift raises critical questions about the future of the industry’s largest trade show. Will MJBizCon thrive under new institutional ownership, or drift within a larger, more diverse portfolio?

Employee turnover isn’t just a staffing headache. It’s also a profit leak. In cannabis retail, where compliance mistakes and customer trust both carry real financial weight, losing a seasoned budtender means losing margin. In today’s industry, retention belongs in the revenue conversation, not the personnel file. Stable teams sell more, make fewer errors, and build repeat customers no marketing budget can buy. The operators who treat workforce stability as infrastructure, not overhead, are the ones quietly outperforming their markets.

In an increasingly competitive landscape, “good enough” is no longer a sustainable business strategy. As cannabis transitions into a true consumer packaged good, the contrast between patchwork processes and precision systems has never been more consequential. Scaling isn’t just about producing more; it’s about producing consistently. Ed Wells examines the critical role of data-driven tools in cultivation and post-harvest operations. His conclusion? Embracing operational rigor is not a departure from cannabis culture, but the essential evolution needed to protect craftsmanship while ensuring long-term success at scale.

For years, Sarah Strickler kept her professional life in the cannabis industry separate from her role as a mother, weighed down by the “smell of judgment.” In this Mother’s Day op-ed, the Grown Rogue co-founder reflects on the 600-percent increase in incarcerated women since the 1980s and the double standards mothers face. Strickler argues that building a responsible industry requires more than transparency; it requires active repair, expungement support, and creating a future where the next generation inherits responsibility and pride rather than the heavy burden of legacy stigma.

The move to reschedule cannabis is facing its first major judicial test. Following a lawsuit by Smart Approaches to Marijuana (SAM), the industry is left wondering if the shift to Schedule III is in jeopardy. While the April 23 order remains in effect for now, the legal challenge introduces new layers of uncertainty for medical and adult-use operators alike. To maintain stability, companies must look beyond the headlines. We break down the two critical factors that will determine whether federal relief arrives on time or hits a roadblock.